A PYMNTS Company

Japan/UK: Takeda will buy Shire in a US$62b deal

By  |  May 8, 2018

Takeda Pharma agreed to buy London-listed Shire for £45.3 billion (US$61.50 billion) on Tuesday, May 8, after the Japanese company raised the amount of cash in its offer to US$30.33 cash and 0.839 shares of Takeda per share of Shire to secure a recommendation, reported The Wall Street Journal.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The deal will be the largest overseas acquisition by a Japanese company and propel Takeda, led by Frenchman Christophe Weber, into the top ranks of global drugmakers.

    “Together, we will be a leader in providing targeted treatments in gastroenterology, neuroscience, oncology, rare diseases and plasma-derived therapies,” he said.

    The tie-up will also be one of the largest ever in the pharmaceuticals sector, reported WSJ.

    Full Content: Wall Street Journal

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.